According to a recent study by Bain & Company, nearly half of all drug launches from 2008 to 2016 underperformed as compared to prelaunch expectations by analysts. The consulting firm found that one-quarter of the new drugs launched in that period did not even reach 50% of external revenue forecasts.

So, how can decisions made during the preclinical phase of drug development increase the chances of a product’s eventual success in a difficult marketplace?

To understand the factors that influence the early drug development journey for small molecules from the view of industry participants, Catalent and BioPharma Dive’s Brand Studio conducted an exclusive survey. Our industry report explores survey respondents’ opinions on why so many new drugs fail to deliver on their promise, and how they plan to avoid those pitfalls with their own compounds.

We'll also explore:

• Why drugs often fail to meet market expectations
• Why designing the optimal dose forms with advanced delivery technologies is critical to patient acceptance and adherence
• How patient needs and preferences drive adherence
• The importance of engaging providers and payers
• Suggestions for increasing the odds of success

​​